Heron Therapeutics (HRTX) PT Raised to $46 at Leerink Partners; 'Focus Moving to HTX-011's Commercialization'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Heron Therapeutics (HRTX) Prices $200M Common Share Offering
June 26, 2018 5:39 AM EDTHeron Therapeutics, Inc. (NASDAQ: HRTX) today announced the pricing of an underwritten public offering of approximately $200 million of shares of its common stock. In addition, Heron has granted the underwriter of the offering a 30-day option to purchase up to an additional approximately $30 million of... More
Heron Therapeutics (HRTX) PT Raised to $80 at Evercore ISI
June 22, 2018 8:33 AM EDTEvercore ISI raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $80.00 (from $56.00) while maintaining a Outperform rating.
... MoreHeron Therapeutics (HRTX) PT Raised to $44 at BofA/Merrill Lynch
June 22, 2018 6:31 AM EDTBofA/Merrill Lynch raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $44.00 (from $33.00) while maintaining a Buy rating.
... MoreHeron Therapeutics (HRTX) PT Raised to $50 at Oppenheimer
June 22, 2018 1:41 AM EDTOppenheimer raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $50.00 (from $34.00) while maintaining a Outperform rating.
... MoreHeron Therapeutics (HRTX) PT Raised to $41 at Mizuho Securities
June 22, 2018 1:38 AM EDTMizuho Securities raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $41.00 (from $35.00) while maintaining a Buy rating.
... MoreHeron Therapeutics (HRTX) PT Raised to $66 at Needham & Company
June 21, 2018 3:48 PM EDTNeedham & Company raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $66.00 (from $42.00) while maintaining a Buy rating.
Analyst Serge Belanger commented, "HRTX reported positive results from two Phase 2b studies in total knee arthroplasty (TKA) and breast augmentation where HTX-011 successfully... More
Heron Therapeutics (HRTX) PT Raised to $54 at Cowen; Sees HTX-011 as $1B+ Opportunity
June 21, 2018 1:15 PM EDTCowen raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $54.00 (from $48.00) while maintaining an Outperform rating after the company announced positive Phase IIb data in TKA and breast augmentation demonstrating superior pain control and opioid reduction compared to placebo and generic bupivacaine. In addition HTX-011... More
Heron Therapeutics (HRTX) PT Raised to $51 at Jefferies
June 21, 2018 11:39 AM EDTJefferies raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $51.00 (from $38.00) while maintaining a Buy rating.
... MoreHeron Therapeutics (HRTX) PT Raised to 'Street High' $80 at Evercore ISI
June 21, 2018 10:23 AM EDTEvercore ISI raised its price target on Heron Therapeutics (NASDAQ: HRTX) to a 'Street High' $80.00 (from $56.00) while maintaining an Outperform rating.
Analyst Josh Schimmer with the rating news.
... More